• Degarelix acetate: Workflow for GnRH Assays

  2026-08-27

  Degarelix acetate gives researchers a rapid, selective way to test GnRH receptor blockade, pituitary hormone regulation, and testosterone-dependent biology. This guide translates receptor assays and the long-term caprine study into practical dose selection, longitudinal sampling, and troubleshooting strategies for prostate cancer research and reproductive endocrinology.

• FOXO3 Dual Metabolic Targeting in Liver Cancer

  2026-08-27

  The reference study identifies FOXO3 as a suppressor of both glycolysis and glutaminolysis in hepatocellular carcinoma through direct transcriptional repression of YAP. Its integrated cell, animal, and patient-derived organoid evidence supports the FOXO3/YAP axis as a mechanistically grounded strategy for limiting metabolic plasticity and HCC growth.

• GANT61: A GLI Inhibitor for Ferroptosis Studies

  2026-08-26

  GANT61 is a selective GLI inhibitor for dissecting GLI1/2-dependent cancer biology. This article connects GLI-mediated transcription inhibition to the GLI2–PRDX1 ferroptosis axis and translates that mechanism into practical assay decisions.

• Norovirus Co-opts NINJ1 for Selective Secretion

  2026-08-26

  Song et al. show that murine norovirus repurposes the membrane-rupture factor NINJ1 to release the viral NS1 protein through a caspase-3-dependent unconventional pathway. The study connects viral immune evasion with regulated cell death and identifies NINJ1 recruitment, oligomerization, and NS1 binding as key mechanistic steps.

• Deuterated Degarelix Acetate: Synthesis and Significance

  2026-08-25

  The reference study reports a practical 13-step synthesis of deuterium-labeled degarelix acetate, using D2O/D3PO4-mediated labeling of a naphthylalanine precursor followed by peptide assembly. The resulting route provides a stable-isotope-labeled material intended to support absorption, distribution, metabolism, and excretion studies of this GnRH receptor antagonist.

• MAPK10–KRT16 Signaling in NSCLC Metastasis

  2026-08-25

  The reference study identifies a phosphorylation-dependent MAPK10/KRT16/RNF213 pathway that limits non-small cell lung cancer metastasis by promoting KRT16 ubiquitination and proteasomal degradation. Its combination of mechanistic protein analysis, cellular motility assays, mouse rescue experiments, and clinical association data supports the axis as a candidate prognostic framework, while leaving important questions about specificity and therapeutic translation.

• Rhodamine 123: Reading Transport Beyond Fluorescence

  2026-08-24

  Rhodamine 123 (chloride) is a powerful live-cell probe for dissecting uptake, efflux, and intracellular retention. This interpretation-first guide explains how to distinguish ABCB1/MDR1 activity from broader transporter effects and apply the dye alongside orthogonal evidence.

• Degarelix Acetate in Long-Term Caprine Chemical Castration

  2026-08-24

  This 2020 goat study shows that repeated subcutaneous degarelix acetate treatment can sustain suppression of testicular endocrine activity and spermatogenesis for at least the treatment interval and early follow-up period. Its value lies in combining hormone measurements, ultrasonography, organ weights, histology, and sperm assessment to evaluate chemical castration rather than relying on testosterone alone.

• Merbromin Inhibits SARS-CoV-2 3CLpro

  2026-08-23

  A 2022 study used activity-based screening of approximately 6,000 compounds to identify merbromin as a selective inhibitor of the SARS-CoV-2 3CLpro protease. Enzyme kinetics, binding assays, and molecular docking supported a mixed-type inhibition model and provide a mechanistic starting point for antiviral inhibitor design, while also highlighting the need for orthogonal validation beyond biochemical assays.

• Panobinostat (LBH589): From HDAC to ECM Biology

  2026-08-22

  Panobinostat (LBH589) is more than a broad-spectrum HDAC inhibitor for oncology studies. This article examines how its epigenetic activity can be used to investigate macrophage–fibroblast signaling, extracellular-matrix remodeling, and form-deprivation myopia while defining practical assay controls and translational limits.

• Testosterone Bounce in Degarelix-Treated Prostate Cancer

  2026-08-22

  A 2024 retrospective study identified testosterone bounce, defined around a 20 ng/dL threshold, as a marker associated with longer overall and cancer-specific survival in patients receiving degarelix acetate. The findings support longitudinal testosterone profiling as a complementary prognostic approach, while emphasizing that the association requires prospective validation before it can guide treatment decisions.

• FPH1 for Functional Hepatocyte Expansion

  2026-08-21

  FPH1 (BRD-6125) supports scalable hepatocyte expansion while preserving function-focused readouts such as albumin and CYP3A4. This guide connects practical dosing, iPSC-derived hepatocyte workflows, and carefully controlled light-regulated gene-expression experiments without overstating evidence for a direct combination.

• Chlorin e6 Workflows for PDT Research

  2026-08-20

  Build reproducible Chlorin e6 experiments across cancer-cell and antibacterial photodynamic therapy models. This guide translates an aligned silk-fibroin scaffold study into practical Ce6 formulation, irradiation, ROS, apoptosis, and wound-infection assay decisions.

• Idoxuridine: From Viral DNA to Translation

  2026-08-20

  Idoxuridine, also known as 5-iodo-2'-deoxyuridine, offers translational researchers a mechanism-proximal way to interrogate viral DNA synthesis, replication disruption, and assay causality. This perspective connects compound handling and experimental validation with a broader strategy for moving antiviral findings toward human-relevant evidence without overstating clinical conclusions.

• Cepharanthine: From Apoptosis to Translation

  2026-08-19

  Cepharanthine, a biscoclaurine alkaloid, is emerging as a translational research asset that connects DNA damage, cell-cycle arrest, mitochondrial apoptosis, organoid validation, and disease-model strategy. This article examines how to evaluate its promise without confusing mechanistic signals with clinical proof.

8526 records 1/569 page Next 12345 下5页 Last page